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Abstract
Background: Influenza is a major public health issue worldwide. It is characterized by episodes of infection that
involve hundreds of millions of people each year. Since that in the seasons 2010–2011 and 2011–2012 the
circulation of FLUB was decreasing we evaluated the clinical presentation, demographic characteristics, admitting
department, and length of stay in children who contracted influenza admitted to Bambino Gesù Children’s Hospital,
during the 2012–2013 influenza season, with the aim to establish if the recover of FLUB was associated to a clinical
worsening, in comparison with those due to FLUA.
Methods: A total of 133 respiratory specimens, collected from patients with symptoms of respiratory tract
infections, positive for the Influenza A and B viruses (FLUA and B) were subtyped. Comparisons between the FLUA
and FLUB groups were performed with the one-way ANOVA for continuous parametric variables, the Mann-Whitney
test for non-parametric variables, or the Chi-Square test or Fisher’s exact test (if cells <5) for categorical variables.
Results: 87.09 % of the FLUA isolates were the H1N1 subtype and 12.90 % were H3N2. Among the FLUB isolates,
91.54 % were the B/Yamagata/16/88 lineage and 8.45 % were the B/Victoria/02/87 lineage. The largest number of
FLUA/H1N1 cases was observed in children less than 1 years old, while the B/Yamagata/16/88 lineage was most
prevalent in children 3–6 years old. Fever was a common symptom for both FLUA and B affected patients.
However, respiratory symptoms were more prevalent in patients affected by FLUA. The median length of stay in
the hospital was 5 days for FLUA and 3 days for FLUB.
Conclusions: The clinical features correlated to different Influenza viruses, and relevant subtypes, were evaluated
concluding that the increasing of FLUB in the season 2012–2013 was without any dramatic change in clinical
manifestation. Our findings suggest, finally, that a stronger commitment to managing patients affected by FLUA is
required, as the disease is more severe than FLUB.
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Background
Influenza is one of the most common respiratory infec-
tious diseases and is responsible for between 3 and 5
million cases of severe influenza illness each year [1].
The influenza viruses are members of the Orthomyxovir-
idae family and contain a single-stranded RNA genome
that is distributed in eight separate segments. There are
three types of Influenza viruses A, B and C [2] that have
different structural arrangements of internal nucleopro-
tein and matrix protein antigens. The segmented
genome may be responsible for the development of pan-
demic strains, whereas mutations (aminoacid substitu-
tions) may be responsible for the development of
influenza epidemics [3].
Influenza typically results in mild-to-moderate ill-
ness in healthy individuals. However, disease severity
tends to increase in children, the elderly, and individ-
uals with chronic medical conditions (pulmonary,
* Correspondence: liviamancinelli12@gmail.com
†Equal contributors
1Virology Unit, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
Full list of author information is available at the end of the article
© 2016 Mancinelli et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mancinelli et al. BMC Infectious Diseases  (2016) 16:6 
DOI 10.1186/s12879-015-1333-x
cardiovascular, liver, renal, and neurological diseases
or immunosuppression).
Children are more susceptible to infection [4] with
annual incidence rates up to 30 % [5]. In particular,
children under 5 years of age are more susceptible to
contracting influenza since they are an immunologic-
ally naïve population [6]. Moreover, they can also be
considered the primary transmitters of influenza in
the community [7, 8] and shed virus at higher viral
titers and for a longer period than adults [9]. Com-
munity based surveillance programs have found that
the H3N2 subtype is detected more frequently in
adults, while H1N1 and Influenza B viruses are de-
tected more often in children [10].
After the beginning of the 2009 H1N1 pandemic, the
Center for Disease Control (CDC) seasonal surveillance
reports documented an increased prevalence of Influ-
enza A virus (FLUA) compared to Influenza B virus
(FLUB) during the 2010–2011 and 2011–2012 influenza
seasons. In the 2012–2013 season FLUA and FLUB were
detected in similar proportions. In Europe, the FLUA
epidemic was primarily caused by the H1N1 subtype,
which outnumbered the H3N2 subtype by in ratio 2:1.
The FLUB epidemic was driven by the B/Yamagata
lineage, which was more prevalent than the B/Victoria
lineage by a ratio of 5:1 [11]. Although a large amount
of data related to influenza surveillance activity is avail-
able [12–14], there are few studies that compare differ-
ences in the clinical presentations of FLUA and B
subtypes isolated in children from Italy.
Since that in the seasons 2010–2011 and 2011–2012
the circulation of FLUB was decreasing, the objective of
this study was to characterize the clinical features,
demographic characteristics, admitting department, and
length of stay in the hospital for children, affected by
FLUA and FLUB, admitted to Bambino Gesù Children’s
Hospital and Research Institute during the 2012–2013
FLU season, with the aim to establish if the remerging of
FLUB was associated to a clinical worsening, in compari-
son with those due to FLUA.
Methods
Design of the study
A retrospective study was conducted analyzing data col-
lected from patients resulted positive for FLU admitted
to Bambino Gesù Children's Hospital and Research In-
stitute from November 2012 to May 2013. Research eth-
ics approval was not necessary as retrospective study in
our Institution, and informed consent was not required
as the data were analyzed anonymously. Patients re-
ceived care in several hospital departments, but the
major departments that provided care were Emergency,
Pediatrics, Surgery, the Intensive Care Unit (ICU), and
the Impaired Immune Function Unit (IIFU). Samples of
throat and nasal swabs (44), nasopharyngeal aspirate
(85), bronchoalveolar lavage (2) and sputum (2) were
processed immediately or stored at −80 °C for up to two
days before testing. The results of testing for the infec-
tious agent and clinical symptoms, underlying disease,
C-reactive protein (CRP), and the patient outcomes were
recorded.
Nucleic acid extraction
Viral DNA and RNA was extracted from 400 μL of spe-
cimen using the EZ1 Virus Mini Kit v. 2.0 on the EZ1
Advanced XL platform (Qiagen, GmbH, Hilden,
Germany) and eluted into 60 μL of elution buffer.
Reverse transcription
Reverse transcription was performed using Applied Bio-
systems (Van Allen Way, Carlsbad, California) reagents
from 10 μL of extracted nucleic acids. Each reaction
contained 5 μL of 10X RT buffer, 11 μL of MgCl2
(25 mM), 2.5 μL of dNTP mix (10 mM), 2.5 μL of ran-
dom hexamer (50 mM), 1 μL of RNase inhibitor (20 U/
mL), 1.25 μL of Reverse Transcriptase (50 U/mL), and
16.75 μL of DEPC water. The thermal cycling parame-
ters were: 25 °C for 10 min, 42 °C for 60 min, and 95 °C
for 5 min.
Routine respiratory virus detection
A multiplex PCR panel able to identify FLU A and B,
Human Metapneumovirus, Adenovirus, Coronavirus
229E/NL63, Parainfluenza viruses 1, 2, and 3, Corona-
virus OC43, Rhinovirus A/B, and Respiratory syncytial A
and B (RV12 ACE Detection 23 Seegene, Seoul, Korea),
using the dual priming oligonucleotide (DPO) system
[15], was used according to the manufacturer’s instruc-
tions. An internal control included in the primer mix-
tures was used to assess any potential PCR inhibitory
effects. All of the samples that tested positive for FLUA
or FLUB were further characterized by genotyping ana-
lysis to identify the subtype. For FLUA subtyping was
performed using a procedure used in our laboratory, in-
stead for FLUB a homebrew procedure was set-up ac-
cording to WHO recommendations [16].
Subtyping influenza A
Each FLUA positive sample was typed using Sanger se-
quencing analysis. The amplified products were purified
using a Purelink™ Quick PCR Purification Kit (Invitrogen
by Life technologies, Löhne, Germany), according to the
manufacturer’s instructions. Sequencing reactions were
performed using the modified standard protocol for the
Big Dye Terminator Cycle Sequencing Kit 3.1 (Applied
Biosystems). Briefly, each reaction contained 2 μL of big
dye terminator, 2 μL of 5X big dye eluent, 1.6 μL of
1 μM FluA primers (Seegene, Seoul, Korea), 1–3.5 μL of
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purified amplified DNA, and water in a final volume of
10 μL. After removing the dye terminator using DyeEx
2.0 (Qiagen), sequencing analysis was performed using
an ABI PRISM 3130xl Genetic Analyzer (Applied Biosys-
tems). All of the original electropherograms were
analyzed using GenBank BLAST software (http://blas-
t.ncbi.nlm.nih.gov/Blast.cgi) to identify the FLUA sub-
type. Identity scores ≥99 % were considered sufficient
for correctly identifying the subtype.
Subtyping influenza B
Each FLUB positive sample was genetically characterized
to discriminate between the B/Yamagata/16/88 and B/
Victoria/02/87 lineages. Each PCR reaction was per-
formed in a final volume of 50 μL and contained 10X
PCR buffer (Applied Biosystems), 25 mM MgCl2,
10 mM deoxynucleoside triphosfate (dNTP), 10 μM for-
ward primer, 10 μM reverse primer, 5 μL of template
cDNA, and 250 units Amplitaq Gold polymerase. The
primers used to identify the Victoria lineage were: the
Bvf224 forward primer (ACATACCCTCGGCAAG
AGTTTC) and the Bvr507 (TGCTGTTTTGTTGT
TGTCGTTTT1) reverse primer. The primers for the
Yamagata reaction were: the Byf226 forward primer
(ACACCTTCTGCGAAAGCTTCA) and the BYr613 re-
verse primer (CATAGAGGTTCTTCATTTGGGTTT).
These primers were chosen based on the recommenda-
tions of the WHO [16]. The amplified products were de-
tected by gel electrophoresis using the Flashgel System,
and 2.2 % agarose gels (Lonza, Basel, Switzerland). The
expected product for the Yamagata lineage was 388 bp
and 284 bp for the Victoria lineage.
Statistical analysis
Data analysis was conducted using the Statistical Pack-
age for the Social Sciences Windows, version 15.0 soft-
ware (SPSS, Chicago, Illinois, USA). The descriptive
statistics consisted of the mean ± standard deviation for
parameters with a Gaussian distribution, which was
confirmed using histograms and the Kolgomorov-
Smirnov test. The median and range (min to max) are
presented for frequencies and categorical variables with
non-Gaussian distributions. Comparisons between the
FLUA and FLUB groups were performed with the one-
way ANOVA for continuous parametric variables, the
Mann-Whitney test for non-parametric variables, or the
Chi-Square test or Fisher’s exact test (if cells <5) for cat-
egorical variables. A p value of <0.05 was considered sta-
tistically significant for all tests.
Results
A total of 133 respiratory samples tested positive for
FLUA (n = 62; 46.61 %) and FLUB (n = 71; 53.38 %). The
most common FLUA subtype was H1N1 detected in 54/
62 (87.1 %) samples while only 8/62 (12.90 %) were the
H3N2 subtype. As expected, the most common FLUB
subtype was the B/Yamagata/16/88 lineage detected in
65/71 (91.54 %) samples. The remaining 6/71 (8.45 %)
FLUB samples were from the B/Victoria/02/87 lineage.
The distribution of FLUA and FLUB patients affected by
each subtype is summarized in Table 1 according to
their demographic characteristics (gender, nationality
and age), clinical symptoms, outcome, underlying condi-
tions, unit of admission/hospitalization, and length of
stay. Among the patients who tested positive for FLUA,
33/62 were female and 29/62 male, while for the FLUB
patients 25/71 were female and 46/71 male (p = 0.320).
All patients involved were between 0 and 16 years old.
The highest number of cases of FLUA/H1N1 was ob-
served in children less than 1 year of age. The FLUB B/
Yamagata/16/88 lineage was most prevalent in children
ranging from 3 to 6 years old. Infections with the less
prevalent FLUA H3N2 and FLUB B/Victoria/02/87
strains were homogeneously distributed across the dif-
ferent age groups (Fig. 1). There were no significant dif-
ferences by one-way ANOVA analysis between the
FLUA and FLUB patients in terms of age (p = 0.370),
weight (p = 0.203), height (p = 0.203), and body mass
index (p = 0.660).
Fever was the most common symptom in FLU positive
patients. In patients with FLUB a fever <38 °C (range:
37–37.9 °C) was significantly more frequent than FLUA
(p = 0.019) and patients affected by FLUA had a
significantly higher frequency of respiratory simptoms
(p = 0.034) than patients with FLUB. Apnea was equally
distributed in FLUA and FLUB patients. No significant
differences were observed between the two groups in
terms of laryngitis, pharyngitis, bronchitis, bronchiolitis,
bronchopneumonia, pneumonia, or pertussis. Twenty
five patients presented with neoplasia/hematological
malignancies or a severe underlying disease, such as
chronic disorders of the pulmonary or cardiovascular
systems, metabolic diseases, and neurological disorders,
that were clustered in congenital and genetic disorders
(Table 1). In patients suffering from underlying dis-
eases, FLUA infection was more prevalent than FLUB
(p = 0.044). The normal concentration of CRP in
healthy human serum ranges from 0 to 0.50 mg/dL.
In the FLU patients, the mean CRP value was 1.71 ±
2.54 for FLUA patients and 1.14 ± 1.72 for FLUB pa-
tients. A value ≥ 0.50 was obtained in 45 % of FLUA
cases and in 46 % of FLUB.
Information related to the department where patients
were admitted is shown in Table 1. Patients accessed the
hospital through the emergency unit in 33.7 % of FLUA
and 66.3 % of FLUB cases (p = 0.017). The median of
length of stay was 5 days (range: 0–59) for FLUA and
3 days (range: 0–116) for FLUB. Community acquired
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influenza infections were equally distributed between the
FLUA and FLUB patients, while among nosocomial in-
fections FLUB was responsible for 90.9 % versus 9.1 % of
FLUA (p = 0.039).
There were no significant differences observed in the
frequency of co-infections between the different types of
FLU. Among the 62 patients infected with FLUA, 18
(29.03 %) co-infections with other respiratory pathogens
were detected, 13 of which were co-infections with re-
spiratory viruses and 5 were with bacteria. In 71 patients
infected with Influenza B, 11 (15.5 %) co-infections were
detected, 7 of which were co-infections with viruses and
4 were with bacteria. There were no co-infections de-
tected in patients with the B/Victoria/02/87 lineage. The
respiratory pathogens responsible for the co-infections
are listed in Table 2.
The distribution of influenza cases during the
2012–2013 season is shown in Fig. 2. The peak inci-
dence of positive cases was between the 5th and 11th
week of 2013. The highest incidence occurred for
FLUA and B in the 7th and 8th week, respectively,
corresponding to the middle of February (Fig. 3). The
first FLUA case was detected at the end of November
2012 and started circulating earlier than FLUB, which
was first detected at the end of December 2012.
Discussion
In this study, a comparison of the clinical features pre-
sented in children admitted to our hospital resulted
positive for FLUA and B infections was analyzed. Bam-
bino Gesù Children’s Hospital is a Reference Pediatric
Centre for the care and treatment of children coming
from central and southern Italy.
FLUB was slightly more prevalent (53.38 %) than
FLUA (46.62 %) in the study population. This is consist-
ent with the 2012–2013 ECDC Surveillance Report that
reported a similar proportion of seasonal FLUA and B in
Europe. However, FLUA peaked and declined slightly be-
fore FLUB and the highest infection frequency was evi-
dent during the “winter season”. Our data show a
similar seasonal trend for FLUA and B; however, in con-
trast to the data reported by the ECDC, the circulation
of FLUA ended later than FLUB.
Table 1 Demographic and clinical characteristics of 133
patients, admitted to Bambino Gesù Children’s Hospital, Rome,
Italy, during the influenza season 2012–2013, positive for FLUA
and B by viral type and subtype











Sex N (%) N (%) N (%) N (%)
Males 26 (19.55) 3 (2.26) 42 (31.58) 4 (3.01)
Females 28 (21.05) 5 (3.76) 23 (17.29) 2 (1.50)
Nationality
Italian 49 (36.84) 8 (6.02) 52 (39.1) 5 (3.76)
European 2 (1.50) 0 5 (3.76) 0
Other 3 (2.26) 0 8 (6.01) 1 (0.75)
Age (years)
< 1 27 (20.3) 2 (1.50) 10 (7.52) 1 (0.75)
1–2 12 (9.02) 1 (0.75) 17 (12.79) 2 (1.50)
3–5 10 (7.52) 1 (0.75) 22 (16.55) 2 (1.50)
6–10 2 (1.50) 2 (1.50) 11 (8.28) 0
> 11 3 (2.26) 2 (1.50) 5 (3.76) 1 (0.75)
Clinical symptoms
Fever >38 °C 37 (27.82) 4 (3.01) 27 (20.3) 4 (3.01)
Fever <38 °C 17 (12.79) 4 (3.01) 38 (28.57) 2 (1.50)
Apnea 7 (5.26) 0 2 (1.50) 0
Respiratory simtomps 29 (21.80) 3 (2.26) 21 (15.79) 3 (2.26)
Outcome
Fever 31 (23.31) 7 (5.26) 39 (29.32) 4 (3.01)
Otitis 2 (1.50) 0 3 (2.26) 0
Laryngitis 1 (0.75) 0 1 (0.75) 0
Pharingitis 1 (0.75) 0 2 (1.50) 0
Bronchitis 4 (3.01) 0 5 (3.76) 1 (0.75)
Bronchiolitis 7 (5.26) 1 (0.75) 1 (0.75) 1 (0.75)
Bronchopneumonia 1 (0.75) 0 0 0
Pneumonia 7 (5.26) 0 11 (8.28) 0
Myositis 0 0 2 (1.50) 0
Pertussis 0 0 1 (0.75) 0
Underlying disease
None 44 (33.08) 3 (2.26) 57 (42.86) 4 (3.01)
Acquired 2 (1.50) 2 (1.50) 7 (5.26) 0
Congenital 5 (3.76) 1 (0.75) 0 (0.00) 2 (1.50)
Genetic 3 (2.26) 2 (1.50) 1 (0.75) 0
Units
Emergency 10 (7.52) 0 27 (20.30) 3 (2.26)
Pediatrics 30 (22.56) 4 (3.01) 24 (18.05) 1 (0.75)
Surgery 2 (1.50) 0 0 0
ICUa 3 (2.26) 1 (0.75) 1 (0.75) 1 (0.75)
Table 1 Demographic and clinical characteristics of 133
patients, admitted to Bambino Gesù Children’s Hospital, Rome,
Italy, during the influenza season 2012–2013, positive for FLUA
and B by viral type and subtype (Continued)
IIFUb 10 (7.52) 2 (1.5) 13 (9.77) 1 (0.75)
Length of stay (days)
Median 5 5 3 3
aIntensive care units
bImpaired immune function units
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Fig. 1 Distribution of FLUA and B in children of different ages
Table 2 Summary of the co-infecting respiratory pathogens (viruses and bacteria) detected in FLUA and B cases
Influenza virus Respiratory pathogens Number (%)
FLUA (H1N1) N/14
Adenovirus 3 (21.43)
Coronavirus 229E 2 (14.29)
Parainfuenza virus 3 1 (7.14)
Rhinovirus 1 (7.14)
Respiratory Syncytial Virus B 2 (14.29)
Bocavirus 1 (7.14)
Respiratory Syncytial Virus A- Coronavirus OC43 1 (7.14)
Haemophylus influenzae 2 (14.29)
Pseudomonas aeruginosa 1 (7.14)
FLUA (H3N2) N/4
Coronavirus 229E 1 (25)
Coronavirus 229E- Rhinovirus 1 (25)
Pseudomonas aeruginosa 1 (25)
Branhamella catarrhalis- Haemophylus influenzae- Staphylococcus aureus 1 (25)
FLUB Yamagata/16/88 lineage N/11
Coronavirus OC43 1 (9.09)
Coronavirus 229E 1 (9.09)
Metapneumovirus 1 (9.09)
Rhinovirus 1 (9.09)
Respiratory Syncytial Virus A 2 (18.19)
Respiratory Syncytial Virus A- Adenovirus 1 (9.09)
Bordetella pertussis 1 (9.09)
Branhamella catarrhalis 1 (9.09)
Haemophylus influenzae- Staphylococcus aureus 1 (9.09)
Streptococcus pyogenes 1 (9.09)
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Our results were consistent too with the prevalence of
FLUA/H1N1 (34 %), FLUA/H3N2 (5 %), and FLUB
(58 %) in Italy during the 2012–2013 flu season reported
to Influnet, a sentinel surveillance system for influenza
[17]. Influnet also reported 3 % of FLUA cases that were
not subtyped. However, these data reflect the whole
population and our data are concerned with only
pediatric patients.
The results of laboratory testing and clinical find-
ings were compared for FLUA and FLUB patients to
investigate clinical differences between the groups. No
consistent differences were observed in the clinical
presentation of patients by subtype viral, according to
results of studies about the clinical characteristics of
patients positive for Influenza A and B [18]. Males
seemed to be more susceptible to contracting FLU
compared to females and, specifically, FLUB. This is
concordant with previous studies in which the greater
humoral and cell-mediated immune responses of fe-
males to viral antigens was demonstrated to play an
important role in determining the gender variability
in viral infections and, in females, being beneficial
against infectious diseases [19]. With regard to the
age distribution, FLUA was more common in children
less than 1 year old, where they can cause more se-
vere infections, confirming previous studies [20, 21],
and FLUB was more common in school age children.
Moreover, length of stay in children with FLUA was
significantly higher than those infected with FLUB, being
the median 5 days (range: 0–59) for FLUA and 3 days
(range: 0–116) for FLUB. Specifically, this long hospital
stay (59 and 116 days) was, for FLUA, in a patient with
Fig. 2 Distribution of influenza cases observed from November 2012 to May 2013
Fig. 3 Weekly distribution of FLUA and B isolates during the 2012–2013 FLU season
Mancinelli et al. BMC Infectious Diseases  (2016) 16:6 Page 6 of 8
complications due to tracheostomy procedure, while for
FLUB a nosocomial infection occurred in a oncoemato-
logical patient. This finding is unsual since that in a pre-
viuos study children with influenza B in comparison
with those infected by A/H1N1 influenza virus had sig-
nificantly higher hospitalization rates (p < 0.05) [20]. Is
possible to speculate that the longer hospitalization for
FLUA patients be correlated to the major cases with
fever >38 °C and respiratory simptoms. No significant
differences were observed in CRP levels between FLUA
and B patients and a similar frequency of patients with
elevated CRP was detected in both FLUA and B. Fever
was confirmed as a major influenza symptom [21, 22]. A
similar number of FLUA and FLUB patients presented
with a temperature ≥38°. However, FLUB patients were
significantly more likely to have a fever <38 °C than
FLUA patients. In contrast, respiratory symptoms were
mainly detected in FLUA patients (Table 1). Pre-existing
diseases condition the clinical expression of Influenza
resulting in a greater number of these children develop-
ing lower respiratory tract infection [23]. We found that
FLU patients with underlying malignancies such as
lymphoma, leukemia, solid tumor, or tubulopathy, were
more susceptible to FLUB infection, in agreement with
data previously reported [24]. In contrast, patients with
congenital diseases (hypoplastic left heart syndrome,
neuromotor disorder, Swyer James syndrome, epilepsy,
cerebral palsy, laryngotracheal cleft, or immune defi-
ciency) and genetic preexisting conditions (cystic fibro-
sis, sickle-cell anemia, trisomy of chromosome 10, or
Niemann Pick disease) were more susceptible to FLUA
infection. This is probably related to FLUA patients
younger than those with FLUB. In our study, 12/133
(9.02 %) of FLU infections were hospital acquired with
FLUB being the principal etiological agent responsible.
Patients that contracted nosocomial infections were
mainly immunosuppressed and admitted through the
IIFU (8 cases FLUB), followed by the pediatrics (2 cases
FLUB and 1 FLUA) and surgery (1 case FLUA) units.
Numerous examples of nosocomial FLU outbreaks have
been reported in long-term care facilities for the elderly.
Experimental evidences supports the fact that humans
generate infectious particles in both respiratory droplets
and aerosols and that their generation is enhanced dur-
ing influenza illness [25]. Moreover, children, who do
not have or minimal immunity against influenza vi-
ruses, and immunocompromised individuals, who can
shed virus for long periods of time at high titers, have
already been pinpointed as good transmitters in com-
parison to healthy adults. However, it is unclear why
FLUB, in comparison to FLUA, should cause a more
severe infection in the group of immunosuppressed
and moreover, in the population object of the study,
the number of patients with malignancies is low and
it is difficult to establish if the difference is really
significant.
In our study there were no significant differences be-
tween co-infections with viral or bacterial pathogens in
FLUA and B patients. All of the co-infections investi-
gated were in children with a mean age less than 5 years.
One death was reported in a FLUA patient affected by
quadriplegia and chronic respiratory failure. It is possible
that FLUA could have been responsible for further im-
peding the patient’s ability to breathe.
There were some limitations in this study. Being a
retrospective study, it was not possible to collect more
clinical data, as well as the information about the vaccin-
ation history of patients that tested positive for FLUA
and B; in addition, this was a single-center study and
only one year was analysed.
Our study was primarily focused on the clinical pres-
entation of FLUA and FLUB infections to provide add-
itional information concerning the clinical presentation
of pediatric influenza. No outcomes due to other re-
spiratory viruses were evaluated. Further studies that de-
scribe how co infections with other viruses impact FLU
infections could be useful. To our knowledge, there is
limited published data regarding the clinical differences
between seasonal FLUA and B in pediatrics after the
2009 pandemics. The main findings from our study con-
firm that, although fever is a major component of influ-
enza A and B presentation, respiratory symptoms were
more severe and the length of the hospital stay was lon-
ger for FLUA patients than FLUB patients concluding
that the increasing of FLUB in the season 2012–2013
was without any dramatic change in clinical manifest-
ation. Although some studies have reported gastrointes-
tinal symptoms such as abdominal pain, diarrhea and
vomiting to be more common with FLUB infection [26],
this was not the case in this study. The different viral
types and subtypes should be routinely identifed by diag-
nostic laboratory to best address clinicians to appropiate
therapeutic measures.
Conclusions
In summary, our results suggest that the clinical features
correlated to different FLU viruses and to the relevant
subtypes should be taken into consideration by health
authorities to implement prevention strategies with the
aim to reduce the number of sick subjects, the preva-
lence of hospitalization, and the circulation of FLU.
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